BioLineRx/BLRX

$1.24

-1.59%
-
1D1W1MYTD1YMAX

About BioLineRx

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Ticker

BLRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Philip Serlin

Employees

49

Headquarters

Modiin, Israel

BioLineRx Metrics

BasicAdvanced
$88.31M
Market cap
-
P/E ratio
-$0.85
EPS
1.37
Beta
-
Dividend rate

What the Analysts think about BioLineRx

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 2 analysts.
1,053.23% upside
High $21.00
Low $7.60
$1.24
Current price
$14.30
Average price target

BioLineRx Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-16M
-13.51%
Profit margin
0%
-

BioLineRx Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 130.77%
QuarterlyAnnual
Q3 22
Q4 22
Q1 23
Q2 23
Q3 23
Actual
-$0.15
-$0.15
-$0.15
-$0.30
-
Expected
-$0.15
-$0.13
-$0.17
-$0.13
-$0.26
Surprise
0%
20%
-11.76%
130.77%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

Buy or sell BioLineRx stock

Buy or sell BioLineRx stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing